Description
Palbociclib is an inhibitor of CDK4 and CDK6 that displays anticancer chemotherapeutic and nephroprotective activities; it is currently in clinical trials as a potential treatment for breast cancer. Palbociclib induces G0/G1 phase cell cycle arrest in renal proximal tubule cells, protecting animals against nephrotoxicity and inflammation induced by other chemotherapeutics. Palbociclib also induces cell cycle arrest in cellular and animal models of glioma, increasing overall survival times. In animal models of retinoblastoma, this compound inhibits cell proliferation, and induces G1 phase cell cycle arrest and tumor regression.